- Home
- DMAC vs MSD Comparison
DMAC vs MSD Comparison
Compare DMAC & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- MSD
- Stock Information
- Founded
- DMAC 2000
- MSD 1993
- Country
- DMAC United States
- MSD United States
- Employees
- DMAC N/A
- MSD N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- MSD Trusts Except Educational Religious and Charitable
- Sector
- DMAC Health Care
- MSD Finance
- Exchange
- DMAC Nasdaq
- MSD Nasdaq
- Market Cap
- DMAC 178.0M
- MSD 144.6M
- IPO Year
- DMAC N/A
- MSD N/A
- Fundamental
- Price
- DMAC $3.63
- MSD $7.86
- Analyst Decision
- DMAC Strong Buy
- MSD
- Analyst Count
- DMAC 2
- MSD 0
- Target Price
- DMAC $8.00
- MSD N/A
- AVG Volume (30 Days)
- DMAC 110.0K
- MSD 70.2K
- Earning Date
- DMAC 08-06-2025
- MSD 01-01-0001
- Dividend Yield
- DMAC N/A
- MSD 11.26%
- EPS Growth
- DMAC N/A
- MSD N/A
- EPS
- DMAC N/A
- MSD N/A
- Revenue
- DMAC N/A
- MSD N/A
- Revenue This Year
- DMAC N/A
- MSD N/A
- Revenue Next Year
- DMAC N/A
- MSD N/A
- P/E Ratio
- DMAC N/A
- MSD N/A
- Revenue Growth
- DMAC N/A
- MSD N/A
- 52 Week Low
- DMAC $2.14
- MSD $6.11
- 52 Week High
- DMAC $6.82
- MSD $7.46
- Technical
- Relative Strength Index (RSI)
- DMAC 46.56
- MSD 60.54
- Support Level
- DMAC $4.02
- MSD $7.63
- Resistance Level
- DMAC $4.17
- MSD $7.91
- Average True Range (ATR)
- DMAC 0.25
- MSD 0.05
- MACD
- DMAC -0.04
- MSD 0.00
- Stochastic Oscillator
- DMAC 37.89
- MSD 77.79
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.